Drug Database
ME

methylphenidate hydrochloride (Jornay PM / HLD200 / HLD 200)

✓ Approved

Ironshore Pharmaceuticals · SLC6A2 · Small Molecule

What is methylphenidate hydrochloride?

methylphenidate hydrochloride is a small molecule developed by Ironshore Pharmaceuticals. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesJornay PM, HLD200, HLD 200
CompanyIronshore Pharmaceuticals
Drug ClassSmall Molecule
Molecular TargetSLC6A2, SLC6A3
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ironshore Pharmaceuticals

Mechanism of Action

Molecular Targets

methylphenidate hydrochloride acts on 2 molecular targets:

SLC6A2solute carrier family 6 member 2 (NAT1, NET)
SLC6A3solute carrier family 6 member 3 (PKDYS, DAT1)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

methylphenidate hydrochloride is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersAttention deficit hyperactivity disorder✓ Approved

Related Research Articles

PubMedCell death and differentiation2026-09-20

ADORA1 inhibition suppresses colon cancer development via hippo tumor suppressor pathway.

Li Zhongbo Z, Liu Zhihao Z, Zhang Xiaobo X, Bao Zhuocong Z et al.

Coffee is one of the most commonly consumed beverages in daily life, with caffeine being the major psychoactive component that acts against fatigue and drowsiness. Epidemiological studies have demonstrated the protective effect of coffee intake on colon cancer risk, recurrence and overall survival, but the detailed mechanisms are unclear. In this study, we identified an adenosine receptor (ADORA) as an important upstream receptor for the Hippo/YAP axis and found that caffeine competitively blocked the activation of ADORA, which subsequently inhibited colon cancer carcinogenesis and progression. Caffeine blocked the activation of ADORA1 and then promoted YAP phosphorylation and deactivation via the Gαi-cAMP/PKA-LATS axis. Interestingly, YAP could bind to the promoter region of ADORA1 and facilitate its transcription, resulting in the formation of a positive feedback loop between Hippo signalling and the adenosine receptor pathway. Our study revealed a novel positive feedback loop between the Hippo/YAP axis and adenosine signalling in colon cancer progression, while the tumour-suppressive function of caffeine provides more guidance for lifestyle intervention for cancer prevention and therapeutics.

PMID 42763325
Read full article →
PubMedIn vitro models2026-09-20

Anti-biofilm and anti-virulence properties of Ricinus communis and Catharanthus roseus leaves against Pseudomonas aeruginosa PAO1.

Gebaly Eman El EE, Taha Mostafa N MN, Ashour Hossam M HM, Khairalla Ahmed S AS

Pseudomonas aeruginosa remains a major concern in clinical microbiology owing to its intrinsic multidrug resistance and its elaborate regulatory networks that enable evasion of host immune responses, particularly through robust biofilm development and the secretion of diverse virulence factors. These pathogenic behaviors are tightly governed by quorum-sensing (QS) systems, prompting increasing interest in exploiting plant-derived compounds as potential anti-virulence therapeutics. In this study, leaf extracts from Ricinus communis and Catharanthus roseus were examined for their capacity to modulate biofilm formation and QS-regulated virulence gene expression in the P. aeruginosa PAO1 strain. The production of key virulence factors was evaluated using multiple standardized assays, including the crystal violet binding assay (biofilm), azocasein assay (protease), chloroform-HCl extraction (pyocyanin), and the orcinol assay (rhamnolipids), while gene expression was quantified via quantitative real-time polymerase chain reaction (qPCR). The findings indicated that the extracts, rich in tannins and flavonoids, did not affect the planktonic growth of PAO1; however, both significantly (P < 0.05) suppressed biofilm formation and attenuated the production of pyocyanin, protease, and rhamnolipids. Additionally, qPCR analysis revealed pronounced downregulation of central QS regulatory genes, lasI, lasR, and rhlR, highlighting the potential of these phytochemicals to disrupt quorum-sensing-mediated pathogenicity.

PMID 42763502
Read full article →
PubMedComprehensive physiology2026-09-20

Axial Connectivity of the Lung Microbiome: A Review of Interorgan Crosstalk.

Palanivel Mathangi M, Narayana Jayanth Kumar JK, Chotirmall Sanjay H SH

The classic organ-centric model of human physiology is rapidly giving way to a unified approach embracing the human body as an integrated network of bidirectional interorgan communication. The human microbiome serves as a fundamental mediator of this shift, regulating immune homeostasis, barrier integrity and metabolic signaling across organs. While the lung maintains a characteristic low-biomass microbiome in dynamic equilibrium, any disruption primes local and systemic immune responses contributing to disease. Beyond the well-described gut-lung axis, crosstalk between the lung and other distal organ systems is lesser recognized; however, increasingly acknowledged as a key under-appreciated contributor to respiratory disease including extrapulmonary complications. This review synthesizes current established evidence on axial connectivity of the lung microbiome across the gut, brain, skin, heart, kidney, and liver, and finds that such crosstalk is predominantly, though not exclusively gut-mediated. Direct lung-organ interactions are described for several axes; however, they remain preliminary. Across these lung-axial systems, common pathophysiological mechanisms emerge, including dysbiosis-induced depletion of microbial metabolites, immunomodulation, and barrier perturbations, all linking pulmonary disease with neuroinflammation, gastrointestinal deficits, and cardiac, renal, hepatic, and dermatological abnormalities. We assess how therapeutic modulation of interorgan systems offers promising avenues for improved risk stratification and novel therapeutics. Recognizing microbiome-mediated pulmonary-organ crosstalk represents an emerging conceptual framework in respiratory medicine, repositioning microbial communities as key modulators of extrapulmonary disease.

PMID 42763526
Read full article →
PubMedOdontology2026-09-20

LL-37-based oral antimicrobial therapeutics: translational challenges and future directions-a narrative review.

J Muruganandhan M, Veeraraghavan Vishnu Priya VP, Govindarajan Sujatha S

LL-37 is an antimicrobial peptide involved in antimicrobial defence, inflammatory regulation, tissue repair, and bone regeneration in the oral cavity. Salivary and gingival crevicular fluid LL-37 levels are associated with disease activity and treatment responses. Although there is solid mechanistic and preclinical data on LL-37, research on clinical applications of this remarkable peptide seem to be stalled due to a multitude of factors. The use of LL-37 in clinical practice is affected by proteolytic degradation, cytotoxicity at higher concentrations, microbial tolerance, biofilm protection, rapid salivary clearance, and high production costs. Our review provides a comprehensive update emphasizing the key gaps in LL-37 research and the translational challenges faced by researchers. We also suggest a three-pronged roadmap to future approaches comprising (i) rational peptide engineering and smart nanocarrier-based delivery, (ii) host-directed induction of endogenous LL-37 via vitamin D and short-chain fatty acid pathways, and (iii) standardisation of salivary/gingival crevicular fluid LL-37 as a non-invasive biomarker, aimed at developing LL-37 as a viable diagnostic and therapeutic agent in periodontal disease, dental caries, endodontic infections, oral mucosal disorders, and oral squamous cell carcinoma. Peptide derivatives, nanocarrier-based delivery systems, combination therapy, and vitamin D-mediated induction are being studied to improve its stability and therapeutic activity. LL-37 may have strong applications in oral diagnosis, prevention, and treatment of oral diseases, if the safety, efficacy, and delivery methods are effectively enhanced.

PMID 42763374
Read full article →
PubMedFood chemistry: X2026-09-19

Comparative multi-omics analysis of microbial succession, metabolite profiles, and antioxidant properties in fermented black and yellow highland barley.

Han Mengru M, Hou Hanghang H, Wang Honglu H, Zhang Miaomiao M et al.

Colored highland barley is rich in bioactive compounds, but fermentation-associated links among microbes, metabolites, and antioxidant properties remain unclear. Black (BHB) and yellow highland barley (YHB) were comparatively fermented using microbial profiling, non-volatile metabolomics, and antioxidant assays. Both cultivars showed reduced microbial diversity, lactic acid bacterial enrichment, fungal dominance by Saccharomycopsis, increased phenolics and anthocyanins, and decreased flavonoids. BHB retained higher flavonoid and anthocyanin contents and stronger radical-scavenging activities, whereas YHB showed greater increases in total phenolics and antioxidant capacity. Both were dominated by late-stage Pediococcus, but YHB had a denser positive bacterial network, whereas BHB showed greater modularity and enrichment of flavonoid- and phenolic acid-related metabolites. YHB was relatively associated with amino acid- and peptide-related metabolites. Lactiplantibacillus and Levilactobacillus were positively associated with selected phenolic metabolites. These findings identify common and cultivar-specific associations among microbial succession, metabolite variation, and antioxidant characteristics during colored highland barley fermentation.

PMID 42761470
Read full article →
PubMedJournal of pain and symptom management2026-09-19

Methylphenidate-Based Interventions for Depressive Symptoms in Palliative Care: A Systematic Review and Meta-Analysis.

Huang Yuhong Y, Tan Chunyan C, Huang Panyun P, Li Daiping D et al.

Depressive symptoms are common in palliative care, but conventional antidepressants are limited by delayed onset and adverse effects. We evaluated randomized evidence on methylphenidate, a faster-acting intervention, for depressive symptoms in adults receiving palliative care. This PRISMA 2020-compliant systematic review and meta-analysis (PROSPERO: CRD420261277228) included randomized controlled trials of methylphenidate-based interventions versus placebo, usual care, or background antidepressants in adults with advanced, life-limiting illness receiving palliative care. Depression-targeted trials provided direct evidence; fatigue-focused trials with depression outcomes provided indirect evidence. Continuous outcomes were pooled as standardized mean differences with random-effects models and Hartung-Knapp sensitivity analysis. Risk of bias was assessed with RoB 2. Five trials (342 participants) were included. Methylphenidate-based interventions were associated with greater improvement in depressive symptoms overall (SMD -0.47, 95% CI -0.81 to -0.13; P = 0.006; I² = 58.9%). Depression-targeted (three trials; SMD -0.62, 95% CI -1.18 to -0.05) and fatigue-focused subgroups (two trials; SMD -0.30, 95% CI -0.53 to -0.07) did not differ significantly (P = 0.307). Depression response was more frequent with methylphenidate (RR 1.78, 95% CI 1.09-2.89; P = 0.021). Risk of bias was low in one, of some concern in three, and high in one. Methylphenidate-based interventions may improve depressive symptoms in selected palliative-care patients, but evidence certainty is very low to low due to small samples, heterogeneity, and indirectness. Findings support cautious, individualized use rather than rapid antidepressant efficacy. Adequately powered trials with depression as a primary endpoint are needed.

PMID 42762836
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about methylphenidate hydrochloride